Form 4: Adverum Biotechnologies CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Laurent Fischer sold 9,126 shares of Adverum Biotechnologies stock to satisfy tax obligations related to vesting and settlement of performance stock units.
Summary
- On May 15, 2025, Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, sold 9,126 shares of common stock.
- The sale was executed to cover tax obligations arising from the vesting and settlement of performance stock units.
- The shares were sold at prices ranging from $1.985 to $2.01, with a weighted-average sale price of $2.
- Following the transaction, Fischer still beneficially owns 87,488 shares of Adverum Biotechnologies stock.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (stock sale for tax obligations) by the CEO. It's neutral to slightly positive as it indicates the CEO has vested stock, but the sale itself doesn't necessarily reflect the company's performance.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of a negative outlook on the company.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of stock sale transaction |
| 05/16/2025 | Date of signature on the Form 4 filing |
Keywords
Adverum Biotechnologies, Laurent Fischer, stock sale, Form 4, tax obligations, ADVM, performance stock units, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.